Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide.
Surveillance for HCC is critical for early detection and treatment, but fewer than one-quarter …

The natural history of metabolic dysfunction-associated steatotic liver disease (MASLD),
previously referred to as non-alcoholic fatty liver disease (NAFLD), is complex and long. A …

Background & Aims Patients with fatty liver disease may experience stigma from the disease
or comorbidities. In this cross-sectional study, we aimed to understand stigma among …

Non-alcoholic fatty liver disease (NAFLD) is a common long-lasting liver disease that affects
millions of people around the world. It is best identified with a hepatic fat build-up that …

Background Denifanstat, an oral fatty acid synthase (FASN) inhibitor, blocks de-novo
lipogenesis, a key pathway driving progressive lipotoxicity, inflammation, and fibrosis in …

Nutrition could prevent or promote non-alcoholic fatty liver disease: an opportunity for
intervention | The BMJ Skip to main content Intended for healthcare professionals Access …

Importance Several oral antidiabetic drug (OAD) classes can potentially improve patient
outcomes in nonalcoholic fatty liver disease (NAFLD) to varying degrees, but clinical data on …

Abstract Background and Aims We examined the impact of a co‐diagnosis of metabolic
dysfunction‐associated steatotic liver disease (MASLD) and type 2 diabetes (T2D) on …

Introduction Metabolic-associated liver diseases have emerged pandemically across the
globe and are clinically related to metabolic disorders such as obesity and type 2 diabetes …

The escalating global prevalence of obesity and its intricate association with the
development of hepatocellular carcinoma (HCC) pose a substantial challenge to public …